The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women The Estée Lauder Companies announced a new five-year commitment to the Breast Cancer Research Foundation to establish the Global…
Vyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND Application Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced that…
IMCD to showcase formulation concepts and sensory experience at In-Cosmetics Latin America 2026 IMCD Group a leading global partner for the distribution and formulation of speciality chemicals and ingredients, will be exhibiting at In-Cosmetics Latin America 2026, on 23 and…
The Gabrail Cancer Center Undertakes Investigator-Initiated Study Evaluating the T-Cell Engager Elranatamab in Combination with Starton Therapeutics’ Controlled Low-Dose Lenalidomide The Gabrail Cancer and Research Center, a PhaseWell Research site, announced that Nashat Gabrail, M.D., has received notification from the…
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans Hyperfine, Inc. the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for…
American Chemical Society Names Syngenta’s Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals Camilla Corsi, Head of Crop Protection Research & Development at Syngenta, is the winner of the prestigious 2026 American Chemical Society (ACS)…
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status Gilead Sciences, Inc. announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult…
NTx Bio Powers Baylor College of Medicine’s Manufacturing of a Personalized Cancer Vaccine in Diakonos Oncology’s Phase 1 Refractory Melanoma Trial NTx Bio, a leader in next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used by researchers at Baylor College…
GenBio AI Builds First World Model of the Human Cell GenBio AI is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford,…
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial Positive topline results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant…
Artera Enrolls First Patient in DIRECT-AI Registry, Marking Milestone in Real-World Evidence Generation for AI-Powered Prostate Cancer Care Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests,announced the enrollment of the first patient in its DIRECT-AI registry…
Silvec Announces EPA Registration for its Novel Therapy Delivery Technology Silvec Biologics Inc., a Maryland-based agricultural biotechnology company, is pleased to announce that its novel RNA-based therapy delivery product is now registered for unconditional commercial use under the U.S. Environmental…